Driehaus Capital Management LLC Sells 15,057 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Driehaus Capital Management LLC lowered its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) by 0.9% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 1,749,922 shares of the biotechnology company’s stock after selling 15,057 shares during the period. Driehaus Capital Management LLC owned 3.19% of Astria Therapeutics worth $15,924,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of ATXS. Quest Partners LLC grew its holdings in Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,112 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in shares of Astria Therapeutics by 135.6% during the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 2,861 shares during the period. Hsbc Holdings PLC bought a new stake in shares of Astria Therapeutics during the second quarter worth approximately $171,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Astria Therapeutics during the first quarter worth approximately $200,000. Finally, Panagora Asset Management Inc. boosted its holdings in shares of Astria Therapeutics by 104.7% during the second quarter. Panagora Asset Management Inc. now owns 30,926 shares of the biotechnology company’s stock worth $281,000 after acquiring an additional 15,816 shares during the period. Institutional investors own 98.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ATXS shares. TD Cowen started coverage on Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 price objective for the company. Wedbush restated an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a report on Tuesday, August 13th. Oppenheimer lifted their price target on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a research report on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Friday. Finally, Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Astria Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $25.20.

Astria Therapeutics Trading Up 0.2 %

NASDAQ ATXS opened at $11.14 on Friday. Astria Therapeutics, Inc. has a 1-year low of $4.26 and a 1-year high of $16.90. The company has a market cap of $611.73 million, a price-to-earnings ratio of -4.80 and a beta of 0.71. The company has a 50 day moving average of $11.33 and a 200-day moving average of $10.83.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). On average, equities research analysts forecast that Astria Therapeutics, Inc. will post -1.66 earnings per share for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.